Información de la revista
Lo más leído
10420
Evolving portal hypertension through Baveno VII recommendationsManuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos
Ann Hepatol. 2024;29:101180
10420
Acceso a texto completo
7779
Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysisShudi Li, Fei Duan, Suling Li, Baoping Lu
Ann Hepatol. 2024;29:101174
7779
Acceso a texto completo

7580
From NAFLD to MASLD: When metabolic comorbidity mattersShan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Ann Hepatol. 2024;29:101281
7580
Acceso a texto completo

6178
Alcohol-related liver disease: A global perspectiveGraciela Elia Castro Narro, Luis Antonio Díaz, Eric Kauffman Ortega, María Fernanda Bautista Garín, Eira Cerda Reyes, Pindaro Sebastian Martinez Delfin, Juan Pablo Arab, Ramón Bataller
Ann Hepatol. 2024;29:101499
6178
Acceso a texto completo
5815
Alcohol-associated liver disease: Epidemiology and managementHelena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller
Ann Hepatol. 2024;29:101162
5815
Acceso a texto completo
5724
A multisociety Delphi consensus statement on new fatty liver disease nomenclatureMary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group
Ann Hepatol. 2024;29:101133
5724
Acceso a texto completo
5464
Pathophysiology of ascites: The importance of the intestine. A surgical contribution to the understanding of a medical problemGabriel E. Gondolesi, Carolina Rumbo, Leonardo Montes, Lucia Novellis, Diego Ramisch, Ariel Riquelme Henríquez, Mariana Ortega, Federico Viano, ... Héctor Solar
Ann Hepatol. 2024;29:101498
5464
Acceso a texto completo
5093
MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney diseaseZiyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam
Ann Hepatol. 2024;29:101512
5093
Acceso a texto completo

5033
Why a pinch of zinc in liver disease mattersKurt Grüngreiff, Dirk Reinhold, Wolfgang Maret
Ann Hepatol. 2024;29:101152
5033
Acceso a texto completo
3887
Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cellsShuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, ... Yu He
Ann Hepatol. 2024;29:101279
3887
Acceso a texto completo
3819
Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Bryan A. Priego-Parra, Arturo Triana-Romero, Génesis P. Martínez-Pérez, Sara A. Reyes-Diaz, Héctor R. Ordaz-Alvarez, Raúl Bernal-Reyes, María E. Icaza-Chávez, Sophia E. Martínez-Vázquez, ... José M. Remes-Troche
Ann Hepatol. 2024;29 Supl 2:101292.4
3819
Acceso a texto completo
3789
The burden of liver disease in Latin AmericaLuis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese
Ann Hepatol. 2024;29:101175
3789
Acceso a texto completo
3522
Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFTJeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon
Ann Hepatol. 2024;29:101280
3522
Acceso a texto completo
3041
Schistosomiasis: A neglected cause of liver disease in the PhilippinesAlexander M. Sy
Ann Hepatol. 2024;29:101166
3041
Acceso a texto completo
2583
Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agentsAndrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra
Ann Hepatol. 2024;29:101182
2583
Acceso a texto completo
2493
From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner
Ann Hepatol. 2024;29:101185
2493
Acceso a texto completo
2293
Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma careInah Marie C. Aquino, Devis Pascut
Ann Hepatol. 2024;29:101176
2293
Acceso a texto completo
2284
A clinical review of congenital hepatic fibrosis diagnosed in adulthood: presentation, complications, and outcomesLauren Loeb, Jason Lewis, Zhongwei Peng, Michael G. Heckman, Raouf Nakhleh, Andrew P. Keaveny
Ann Hepatol. 2024;29:101164
2284
Acceso a texto completo
2260
Palliative care and end stage liver disease: A cohort analysis of palliative care use and factors associated with referralHugo M Oliveira, Helena Pessegueiro Miranda, Francisca Rego, Rui Nunes
Ann Hepatol. 2024;29:101518
2260
Acceso a texto completo
2155
Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western CroatiaMarina Bubonja-Šonje, Dolores Peruč, Maja Abram, Bojana Mohar-Vitezić
Ann Hepatol. 2024;29:101156
2155
Acceso a texto completo